KB-1393

Envafolimab

33705

Background of Envafolimab

Envafolimab, an anti-programmed death ligand 1 (PD-L1) antibody administered via subcutaneous injection, is currently under development for addressing diverse solid tumors and chronic hepatitis B in China. In the United States, its applications encompass soft tissue sarcomas and biliary tract cancer. Distinguished by its single-domain nature, envafolimab stands out for its heightened solubility and expedited tissue penetration compared to full monoclonal antibodies. This characteristic facilitates its subcutaneous administration route. Following the pivotal phase II trial results, SC envafolimab recently secured approval in China for treating adult patients grappling with previously-treated microsatellite instability-high (MSI-H) or deficient MisMatch Repair (dMMR) advanced solid tumors.

Specifications

Catalog Number	KB-1393
Antibody Name	Envafolimab
Isotype	Human IgG1
FC Muations	C220S/D265A/P331G
Target	PDL1
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021.
Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3:17004.